Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0TKRMA
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
39914224 Ate-39
|
|||||
| Synonyms |
Ate-39
Click to Show/Hide
|
|||||
| Organization |
ShanghaiTech University.; Shanghai Clinical Research and Trial Center.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4.11
|
|||||
| Structure |
|
|||||
| Antibody Name |
Atezolizumab
|
Antibody Info | ||||
| Antigen Name |
Programmed cell death 1 ligand 1 (CD274)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Phenoxy silyl linker 39
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 15.88 nM | Moderate PD-L1 expression (PD-L1++) | ||
| Method Description |
The starting point of the small molecule drug was 500 nM, and the drug was diluted 5 times sequentially, for a total of eight concentration points. Cells were laid on 96-well plate at 4000 cells/well, cultured overnight and were added with diluted drugs, in the incubator for 72 h. All cells incubated with the drug were tested for cell viability using Cell Counting Kit-8 (CCK-8) kit (Meilunbio, Dalian, China).
Click to Show/Hide
|
||||
| In Vitro Model | Colon carcinoma | HCT116 cells | CVCL_0291 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 25.55 nM | Moderate PD-L1 expression (PD-L1++) | ||
| Method Description |
The starting point of the small molecule drug was 500 nM, and the drug was diluted 5 times sequentially, for a total of eight concentration points. Cells were laid on 96-well plate at 4000 cells/well, cultured overnight and were added with diluted drugs, in the incubator for 72 h. All cells incubated with the drug were tested for cell viability using Cell Counting Kit-8 (CCK-8) kit (Meilunbio, Dalian, China).
Click to Show/Hide
|
||||
| In Vitro Model | Colon carcinoma | HCT116 cells | CVCL_0291 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 25.7 nM | Positive PD-L1 expression (PD-L1+++/++) | ||
| Method Description |
The starting point of the small molecule drug was 500 nM, and the drug was diluted 5 times sequentially, for a total of eight concentration points. Cells were laid on 96-well plate at 4000 cells/well, cultured overnight and were added with diluted drugs, in the incubator for 72 h. All cells incubated with the drug were tested for cell viability using Cell Counting Kit-8 (CCK-8) kit (Meilunbio, Dalian, China).
Click to Show/Hide
|
||||
| In Vitro Model | Glioblastoma | U87 cells | CVCL_0022 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 68.49 nM | Moderate PD-L1 expression (PD-L1++) | ||
| Method Description |
The starting point of the small molecule drug was 500 nM, and the drug was diluted 5 times sequentially, for a total of eight concentration points. Cells were laid on 96-well plate at 4000 cells/well, cultured overnight and were added with diluted drugs, in the incubator for 72 h. All cells incubated with the drug were tested for cell viability using Cell Counting Kit-8 (CCK-8) kit (Meilunbio, Dalian, China).
Click to Show/Hide
|
||||
| In Vitro Model | Colon carcinoma | HCT116 cells | CVCL_0291 | ||
References